Literature DB >> 18185064

Bombesin-related peptides and their receptors: recent advances in their role in physiology and disease states.

Nieves Gonzalez1, Terry W Moody, Hisato Igarashi, Tetsuhide Ito, Robert T Jensen.   

Abstract

PURPOSE OF REVIEW: Mammalian bombesin-related peptides, gastrin-releasing peptide and neuromedin B actions are mediated by two receptors (BB1-receptor, BB2-receptor), which are closely related to the orphan receptor BRS-3 (BB3-receptor). The purpose of this review is to highlight advances in the understanding of these peptides in physiology/disease states. RECENT
FINDINGS: Pharmacologic/receptor-knockout studies show involvement of these receptors in a number of new processes/diseases. Neuromedin B/BB1-receptor is an important physiological regulator of pituitary-thyroid function; in mediating behavior, especially feas/anxiety; in mediating satiety through different cascades than gastrin-releasing peptide/BB2 receptors and for its autocrine tumor-growth effects. Gastrin-releasing peptide/BB2-receptor plays important roles in mediating signals for pruritus, lung development/injury, small intestinal mucosal defense, and central nervous system processes such as learning/memory. The signaling mechanisms of its potent growth effects are being elucidated and their possible therapeutic targets identified. BB3-receptor knockout mice provided insights for their obesity/glucose intolerance and demonstrated that this receptor may be important in the lung response to injury, tumor growth and gastrointestinal motility. Each receptor is frequently overexpressed in human tumors and has potent growth effects. This effect is being explored to develop new antitumor treatments, such as bombesin-receptor ligands conjugated to cytotoxic agents.
SUMMARY: This receptor family is involved in an increasing number of central nervous system/peripheral processes physiologically and in disease states, and increased understanding of its role may lead to novel treatments.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18185064      PMCID: PMC2631407          DOI: 10.1097/MED.0b013e3282f3709b

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  86 in total

1.  Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer.

Authors:  Qing Zhang; Neil E Bhola; Vivian Wai Yan Lui; Doris R Siwak; Sufi M Thomas; Christopher T Gubish; Jill M Siegfried; Gordon B Mills; Dong Shin; Jennifer Rubin Grandis
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

2.  PPARalpha and AP-2alpha regulate bombesin receptor subtype 3 expression in ozone-stressed bronchial epithelial cells.

Authors:  Yu-rong Tan; Xiao-qun Qin; Yang Xiang; Tao Yang; Fei Qu; Yue Wang; Hui-jun Liu; H Christian Weber
Journal:  Biochem J       Date:  2007-07-01       Impact factor: 3.857

3.  Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer.

Authors:  Celia A Kanashiro; Andrew V Schally; Marta Zarandi; Brian D Hammann; Jozsef L Varga
Journal:  Int J Oncol       Date:  2007-04       Impact factor: 5.650

4.  Role of gastrin-releasing peptide and neuromedin B in anxiety and fear-related behavior.

Authors:  Tania Bédard; Christine Mountney; Pam Kent; Hymie Anisman; Zul Merali
Journal:  Behav Brain Res       Date:  2007-01-31       Impact factor: 3.332

5.  Gastrin releasing peptide and neuropeptide Y exert opposing actions on circadian phase.

Authors:  George J Kallingal; Eric M Mintz
Journal:  Neurosci Lett       Date:  2007-06-08       Impact factor: 3.046

Review 6.  Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours.

Authors:  Martijn Van Essen; Eric P Krenning; Marion De Jong; Roelf Valkema; Dik J Kwekkeboom
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

7.  [64Cu-NOTA-8-Aoc-BBN(7-14)NH2] targeting vector for positron-emission tomography imaging of gastrin-releasing peptide receptor-expressing tissues.

Authors:  Adam F Prasanphanich; Prasant K Nanda; Tammy L Rold; Lixin Ma; Michael R Lewis; Jered C Garrison; Timothy J Hoffman; Gary L Sieckman; Said D Figueroa; Charles J Smith
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-12       Impact factor: 11.205

Review 8.  Radiolabelled regulatory peptides for imaging and therapy.

Authors:  W A P Breeman; D J Kwekkeboom; E de Blois; M de Jong; T J Visser; E P Krenning
Journal:  Anticancer Agents Med Chem       Date:  2007-05       Impact factor: 2.505

9.  Gastrin-releasing peptide activates Akt through the epidermal growth factor receptor pathway and abrogates the effect of gefitinib.

Authors:  Xuwan Liu; Diane L Carlisle; Michelle C Swick; Autumn Gaither-Davis; Jennifer R Grandis; Jill M Siegfried
Journal:  Exp Cell Res       Date:  2007-02-03       Impact factor: 3.905

10.  Capsaicin treatment differentially affects feeding suppression by bombesin-like peptides.

Authors:  Ellen E Ladenheim; Susan Knipp
Journal:  Physiol Behav       Date:  2007-02-08
View more
  57 in total

1.  Pharmacology of putative selective hBRS-3 receptor agonists for human bombesin receptors (BnR): affinities, potencies and selectivity in multiple native and BnR transfected cells.

Authors:  Veronica Sancho; Terry W Moody; Samuel A Mantey; Alessia Di Florio; Hirotsugu Uehara; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2010-05-12       Impact factor: 3.750

2.  Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.

Authors:  Eik Hock Tan; Soon Whatt Goh
Journal:  World J Radiol       Date:  2010-02-28

Review 3.  Bombesin receptor-mediated imaging and cytotoxicity: review and current status.

Authors:  Veronica Sancho; Alessia Di Florio; Terry W Moody; Robert T Jensen
Journal:  Curr Drug Deliv       Date:  2011-01       Impact factor: 2.565

4.  Design, synthesis, and biological evaluation of an antagonist-bombesin analogue as targeting vector.

Authors:  Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever
Journal:  Bioconjug Chem       Date:  2008-09-23       Impact factor: 4.774

Review 5.  Insights into bombesin receptors and ligands: Highlighting recent advances.

Authors:  Irene Ramos-Álvarez; Paola Moreno; Samuel A Mantey; Taichi Nakamura; Bernardo Nuche-Berenguer; Terry W Moody; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2015-05-11       Impact factor: 3.750

Review 6.  Bombesin receptor subtype 3 as a potential target for obesity and diabetes.

Authors:  Nieves González; Paola Moreno; Robert T Jensen
Journal:  Expert Opin Ther Targets       Date:  2015-06-12       Impact factor: 6.902

7.  Pharmacology and selectivity of various natural and synthetic bombesin related peptide agonists for human and rat bombesin receptors differs.

Authors:  Hirotsugu Uehara; Nieves González; Veronica Sancho; Samuel A Mantey; Bernardo Nuche-Berenguer; Tapas Pradhan; David H Coy; Robert T Jensen
Journal:  Peptides       Date:  2011-06-28       Impact factor: 3.750

8.  The molecular basis for high affinity of a universal ligand for human bombesin receptor (BnR) family members.

Authors:  Hirotsugu Uehara; Simon J Hocart; Nieves González; Samuel A Mantey; Tomoo Nakagawa; Tatsuro Katsuno; David H Coy; Robert T Jensen
Journal:  Biochem Pharmacol       Date:  2012-07-22       Impact factor: 5.858

9.  Anti-EGFR therapy combined with neuromedin B receptor blockade induces the death of DAOY medulloblastoma cells.

Authors:  Mariane Jaeger; Carolina Nör; Caroline Brunetto de Farias; Ana Lucia Abujamra; Gilberto Schwartsmann; Algemir Lunardi Brunetto; Rafael Roesler
Journal:  Childs Nerv Syst       Date:  2013-10-03       Impact factor: 1.475

10.  Facilitation of the inhibitory transmission by gastrin-releasing peptide in the anterior cingulate cortex.

Authors:  XiaoYan Cao; Valentina Mercaldo; Pingyang Li; Long-Jun Wu; Min Zhuo
Journal:  Mol Pain       Date:  2010-09-13       Impact factor: 3.395

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.